-

Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company’s first Chief Policy Officer. In this new role, Autor will collaborate with other stakeholders, including consumers, telehealth platforms, providers, advocacy groups, medical associations, pharmaceutical companies, medtech innovators, policymakers, and regulators, with the goal of paving the way to the healthcare of the future - where the power of technology will be combined with the best of personalized care. She will lead the company’s global public policy, regulatory, and government affairs functions.

A former senior leader at the FDA, prosecutor for DOJ, and leader in the pharma industry and nonprofit sector, Deb Autor is a trusted visionary voice in health policy. She brings more than three decades of experience to help Hims & Hers ensure that innovation and integrity move hand in hand. Autor has played a key role in guiding Hims & Hers as a member of the Board of Directors since 2024.

“Extraordinary innovation in areas such as AI, robotics, and at-home diagnostics provides an opportunity to reshape how we deliver access to healthcare,” said Deb Autor, Chief Policy Officer at Hims & Hers. “Now is the time to harness new technologies to make care more proactive, personal, and accessible. Hims & Hers is setting a new standard for what responsible progress in healthcare looks like, and I’m excited to help shape the policies that will make that future a reality.”

Autor previously served as Deputy Commissioner for Global Regulatory Operations and Policy at the FDA, where she directed worldwide inspections, enforcement, and international engagement efforts. Earlier in her career, she led enforcement and policymaking for drug requirements at the FDA’s Office of Compliance for the Center for Drug Evaluation and Research, and represented the FDA as a trial attorney for the U.S. Department of Justice. More recently in the private sector, Autor’s roles include Global Head of Regulatory Excellence at AstraZeneca and CEO of Healthcare Innovation Catalysts.

“As digital health continues to evolve, the policies we shape today will define access, safety, and innovation for years to come,” said Andrew Dudum, CEO and co-founder of Hims & Hers. “Deb’s unparalleled regulatory experience and forward-looking vision make her the ideal leader to guide our engagement with stakeholders at this pivotal moment.”

Autor’s appointment marks a significant milestone in Hims & Hers’ evolution as the company continues to scale its engagement with regulators and policymakers. Her leadership will guide the company’s efforts to shape a modern regulatory framework that combines innovation with accountability, ensuring consumers can confidently access safe, effective, and trusted care online. Autor will also continue to serve as a member of the Hims & Hers Board of Directors.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

Contacts

Javier Lacayo
press@forhims.com

Hims & Hers

NYSE:HIMS

Release Versions

Contacts

Javier Lacayo
press@forhims.com

More News From Hims & Hers

Hims Expands Testosterone Care with Injectable and Oral TRT, Its Largest Men’s Health Launch to Date

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the launch of new injectable and oral testosterone replacement therapies (TRT) for eligible men. It’s the largest expansion of the company’s men’s health program since first introducing the category last September, giving eligible men more options to treat low testosterone in partnership with licensed providers through Hims. An estimated 20 million men1,2 i...

Hims & Hers to Announce Third Quarter 2026 Financial Results on November 9, 2026

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading global health and wellness platform, today announced that it will report third quarter 2026 financial results after the market closes on Monday, November 9, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (833) 461-5787 for U.S. participants and (585) 542-9983 for international participant...

Hers Launches in Australia, Built to Care for the Whole Woman

SYDNEY--(BUSINESS WIRE)--Hims & Hers, the leading global health and wellness platform, today announced the official launch of Hers in Australia, bringing its personalised care platform to women nationwide for the first time. The launch introduces first-of-their-kind treatment programs across Hair, Menopause and Perimenopause, and Weight Loss care - backed by women's-only research and 24/7 Care Team access. The launch marks the rebrand of Juniper, Eucalyptus' women's health platform, which h...
Back to Newsroom